Prime Medicine completes first in-body DNA edit in Wilson’s disease trial
Briefing by News4U · First published
ITHome reports that U.S. biotech firm Prime Medicine announced in early October it had used its Prime Editing platform to directly rewrite DNA inside a Wilson’s disease patient—the first such in-body edit—during a global trial; the first participant was treated this month, with initial safety and efficacy results expected in 2027. [1]
Sources
- 全球首例，美国一公司完成在人体内直接编辑 DNA 试验
ITHome · · Summary only